Table 3.

Predicting future new onset HFpEF with five biomarkers

	Unadj. OR [95% CI]	p	Adj. OR [95% CI]	p	AUC
Gal3 Baseline	1.08 [0.99,1.18]	ns	1.08 [0.97,1.21]	ns	0.62 [0.50,0.74]
Gal3 Follow-up	1.15 [1.03,1.28]	0.011	1.17 [1.02,1.34]	0.027	0.67 [0.55,0.78]
Gal3 delta	1.04 [0.90,1.22]	ns	1.32 [1.04,1.67]	0.024	0.63 [0.50,0.76]
sST2 Baseline	1.04 [0.98,1.09]	ns	1.06 [1.00,1.13]	ns	0.56 [0.43,0.69]
sST2 Follow-up	1.03 [0.99,1.08]	ns	1.03 [0.97,1.08]	ns	0.55 [0.43,0.67]
sST2 delta	1.03 [0.95,1.11]	ns	1.01 [0.93,1.10]	ns	0.51 [0.37,0.65]
IL6 Baseline	1.28 [0.91,1.80]	ns	1.28 [0.89,1.85]	ns	0.62 [0.50,0.74]
IL6 Follow-up	1.08 [0.78,1.49]	ns	1.11 [0.72,1.71]	ns	0.61 [0.49,0.73]
IL6 delta	0.81 [0.56,1.16]	ns	0.76 [0.51,1.14]	ns	0.54 [0.40,0.68]
hsTropI Baseline	1.19 [1.03,1.38]	0.017	1.21 [1.04,1.42]	0.017	0.62 [0.49,0.76]
hsTropI Follow-up	1.19 [1.03,1.37]	0.016	1.07 [0.93,1.22]	ns	0.65 [0.53,0.77]
hsTropI delta	1.14 [0.92,1.40]	ns	1.07 [0.85,1.35]	ns	0.58 [0.44,0.72]
ln(BNP) Baseline	2.85 [1.62,5.02]	< .001	2.71 [1.47,5.01]	0.001	0.74 [0.63,0.86]
ln(BNP) Follow-up	5.16 [2.34,11.4]	< .001	5.13 [2.14,12.3]	< .001	0.81 [0.71,0.90]
ln(BNP) delta	1.58 [0.79,3.16]	ns	1.70 [0.79,3.64]	ns	0.58 [0.45,0.71]
All markers model—Baseline	–	–	–	–	0.82 [0.73,0.92]
All markers model—Follow-up	–	–	–	–	0.86 [0.79,0.94]
All markers model—delta	–	–	–	–	0.68 [0.55,0.81]

Adj. OR Odds Ratio Adjusted for all other biomarkers at corresponding time-point, Gal3 Galectin-3, sST2 soluble suppression of tumorigenicity 2, IL6 interleuckin 6, hsTroponin high sensitivity troponin I, BNP b-type natriuretic peptide